Avalon GloboCare Reports Increased Q1 Loss Amid Rising Costs and Mixed Financial Performance

Avalon GloboCare Corp. (NASDAQ: AVCO), has released its quarterly report for the period ending March 31, 2025. Here's a brief overview of the company's financial performance and key statistics, highlighting both positive and negative aspects from the income statement.

Key Stats:

• Net Loss: $2,482,111 for Q1 2025 vs. $1,367,513 for Q1 2024 (81.5% increase).
• Income from Equity Method Investment: $392,677 for Q1 2025 vs. $107,469 for Q1 2024 (264.7% increase).
• Real Property Rental Revenue: $349,800 for Q1 2025 vs. $314,588 for Q1 2024 (11.2% increase).
• Total Current Assets: $2,794,258 at March 31, 2025, down from $3,236,498 at December 31, 2024.
• Total Current Liabilities: $14,449,353 at March 31, 2025, up from $13,882,555 at December 31, 2024.
• Working Capital Deficit: $11,655,095 at March 31, 2025, an increase from $10,646,057 at December 31, 2024.

Positive Aspects:

• Real property rental revenue saw a positive growth, suggesting good occupancy levels, which increased operating income from real property by 34.9% year-over-year.
• Income from equity investments in Lab Services MSO increased substantially, reflecting strong operational performance prior to its redemption.
• The company recorded higher operational income from its real estate segment despite other increasing operational costs.

Negative Aspects:

• Net loss significantly increased, indicating deteriorating financial health with larger operational losses attributed to high professional fees and operational costs.
• Overall working capital deficit has increased, raising concerns about liquidity and the company's ability to meet its liabilities.
• Significant expenses in professional fees driven by consulting and legal services linked to ongoing business initiatives like the potential merger with YOOV Group Holding Limited.
• Cash balance decreased markedly from $2,856,309 at the end of Q4 2024 to $1,369,586 by March 31, 2025, indicating rising cash burn rates.

Outlook:

Avalon GloboCare’s future hinges on its ability to raise capital, successfully commercialize its KetoAir device, and stabilize its cash flow. Addressing high financial liabilities and managing operational costs will be critical as the company strives to turn around its fortunes while ensuring compliance and maintaining stakeholder confidence.